Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Mycophenolate Mofetil in Relapsing MOGAD
NCT07917247Phase 3Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2026
- Primary completion
- May 2028
01
Overview
A Phase 3 trial of secukinumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), sponsored by Chinese PLA General Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on NCT07917247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917247.